These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2746720)

  • 1. Sustained-release theophylline pharmacokinetics in the cat.
    Dye JA; McKiernan BC; Jones SD; Neff-Davis CA; Koritz GD
    J Vet Pharmacol Ther; 1989 Jun; 12(2):133-40. PubMed ID: 2746720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronopharmacokinetics of theophylline in the cat.
    Dye JA; McKiernan BC; Neff-Davis CA; Koritz GD
    J Vet Pharmacol Ther; 1990 Sep; 13(3):278-86. PubMed ID: 2231868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of an extended-release theophylline product in cats.
    Guenther-Yenke CL; McKiernan BC; Papich MG; Powell E
    J Am Vet Med Assoc; 2007 Sep; 231(6):900-6. PubMed ID: 17867974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral bioavailability of slow-release theophylline from unencapsulated beads in preschool children with chronic asthma.
    Vaughan LM; Milavetz G; Weinberger MM; Smith GD; Harris JB
    Ther Drug Monit; 1988; 10(4):395-400. PubMed ID: 3059587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse.
    Goetz TE; Munsiff IJ; McKiernan BC
    J Vet Pharmacol Ther; 1989 Dec; 12(4):369-77. PubMed ID: 2614856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The consistency of theophylline absorption from a sustained-release formulation in asthmatic children.
    Hill M; Haltom JR; Szefler SJ
    Pharmacotherapy; 1988; 8(5):277-83. PubMed ID: 3255299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
    Rogers RJ; Wiener MB; Hill MR; Szefler SJ
    Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent inconsistent theophylline absorption from sustained release capsules.
    Uden DL; Schaber DE; Wyatt RA
    Clin Pediatr (Phila); 1987 Jun; 26(6):285-7. PubMed ID: 3581636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-a-day dosing with theophylline: a comparison of four sustained-release products.
    Minotti DA; Altman LC; Ayars GH; Popick FR; Benn VJ
    Ann Allergy; 1992 Jun; 68(6):500-6. PubMed ID: 1610026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability of two sustained-release theophylline formulations in the dog.
    Mengozzi G; Intorre L; Bertini S; Giorgi M; Soldani G
    Pharmacol Res; 1998 Dec; 38(6):481-5. PubMed ID: 9990658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
    Bach JE; Kukanich B; Papich MG; McKiernan BC
    J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
    Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
    J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
    Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
    Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.